Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

XAV-939

XAV-939
XAV-939 (NVP-XAV939) is a Tankyrase (TNKS) inhibitor that inhibits TNKS1 and TNKS2 (IC50=11/4 nM). XAV-939 selectively inhibits Wnt/β-catenin-mediated transcription.
Catalog No. T1878Cas No. 284028-89-3
Select Batch
Purity:99.04%
Contact us for more batch information

Resource Download

XAV-939

Catalog No. T1878Alias XAV939, NVP-XAV939Cas No. 284028-89-3

XAV-939 (NVP-XAV939) is a Tankyrase (TNKS) inhibitor that inhibits TNKS1 and TNKS2 (IC50=11/4 nM). XAV-939 selectively inhibits Wnt/β-catenin-mediated transcription.
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Pack SizePriceAvailabilityQuantity
5 mg$48In Stock
10 mg$59In Stock
25 mg$111In Stock
50 mg$179In Stock
100 mg$276In Stock
200 mg$490In Stock
1 mL x 10 mM (in DMSO)$54In Stock
Bulk & Custom
Add to Cart
Questions
View More

Related Compound Libraries of "XAV-939"

Product Introduction

Bioactivity
Description
XAV-939 (NVP-XAV939) is a Tankyrase (TNKS) inhibitor that inhibits TNKS1 and TNKS2 (IC50=11/4 nM). XAV-939 selectively inhibits Wnt/β-catenin-mediated transcription.
Targets&IC50
TNKS2:4 nM (cell free), TNKS1:11 nM (cell free)
In vitro
METHODS: Human colorectal cancer cells SW480 were treated with XAV-939 (1 µM) for 16 h. The expression levels of target proteins were detected by Western Blot.
RESULTS: XAV-939 decreased the abundance of β-catenin and increased the abundance of axin and p-β-catenin in SW480 cells. [1]
METHODS: Normal human epidermal keratinocytes NHEK were treated with XAV-939 (10-50 µM) and rhIL-6 (50 ng/mL) for 24 h, and the number of target cells was detected by APC BrdU flow kit.
RESULTS: XAV-939 largely inhibited the over-proliferation of NHEK. [2]
In vivo
METHODS: To investigate the in vivo function of Wnt signaling, XAV-939 (1 mg/mL, 100 μL, 10% DMSO/90% 0.9% NaCl) was administered intraperitoneally to an IMQ-induced psoriasis mouse model once daily for seven days.
RESULTS: Administration of XAV-939 resulted in a significant reduction of IMQ-induced epidermal hyperplasia and dermal inflammatory infiltration in mice. XAV-939 administration significantly reduced the infiltration of F4/80+ macrophages and CD3+ T cells in IMQ-induced inflammatory dermal lesions.Wnt signaling is critical for IMQ-mediated epidermal hyperplasia. [2]
METHODS: To assay antitumor activity in vivo, paclitaxel (10 mg/kg) and XAV-939 (10 mg/kg) were injected intraperitoneally twice weekly for four weeks into BALB/c nude mice harboring human mammary carcinoma tumor MDA-MB-231.
RESULTS: The combination of paclitaxel and XAV-939 effectively inhibited the growth of mammary tumors compared with control and each single treatment. [3]
Cell Research
XAV939, the recently identified small molecule shown to specifically inhibit PARP activity of tankyrase 1 (and tankyrase 2 at higher concentrations), was used here at much lower concentrations than 3-AB. The tankyrase specific inhibitor XAV939 was solubilized in DMSO at 55°C to a stock concentration of 10mM, which was diluted to a working concentration of 100μM; final concentrations of 0.5μM or 1μM were well within the concentration parameters suggested for cell culture experiments to inhibit tankyrase specifically. Cultures were maintained under these conditions for the duration of the designated time course. Controls were exposed to DMSO alone. Following treatment, cells were lysed and prepared for western blot analysis. Tankyrase 1 and DNA-PKcs protein levels were normalized to the β-actin loading controls and quantified [1].
Animal Research
XAV-939, a selective inhibitor of tankyrase (TNKS)-1 and TNKS-2, was injected i.p., at a dose of 1 mg/ml, once a day for seven consecutive days of IMQ treatment (injection volume 100 μl). Control mice were injected with 100 μl 10% DMSO/90% 0.9% NaCl, the solvent for XAV-939 [3].
AliasXAV939, NVP-XAV939
Chemical Properties
Molecular Weight312.31
FormulaC14H11F3N2OS
Cas No.284028-89-3
Storage & Solubility Information
StoragePowder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
Solubility Information
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 1.25 mg/mL (4 mM), Suspension. Working solution is recommended to be prepared and used immediately.
DMSO: 12.5 mg/mL (40.02 mM)
Solution Preparation Table
10% DMSO+40% PEG300+5% Tween 80+45% Saline/DMSO
1mg5mg10mg50mg
1 mM3.2019 mL16.0097 mL32.0195 mL160.0973 mL
DMSO
1mg5mg10mg50mg
5 mM0.6404 mL3.2019 mL6.4039 mL32.0195 mL
10 mM0.3202 mL1.6010 mL3.2019 mL16.0097 mL
20 mM0.1601 mL0.8005 mL1.6010 mL8.0049 mL

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
TargetMol | Animal experimentsFor example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . TargetMol | Animal experiments A total of 10 animals were administered, and the formula you used is 5% TargetMol | reagent DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。
Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSOTargetMol | reagent (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
Preparation method for in vivo formula: Take 50 μL DMSOTargetMol | reagent main solution, add 300 μLPEG300TargetMol | reagent mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2OTargetMol | reagent mix well and clarify
For Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
%Tween 80
%ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords

Related Tags: buy XAV-939 | purchase XAV-939 | XAV-939 cost | order XAV-939 | XAV-939 chemical structure | XAV-939 in vivo | XAV-939 in vitro | XAV-939 formula | XAV-939 molecular weight